Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;21(2):227-237.
doi: 10.1038/s41589-024-01671-9. Epub 2024 Jul 4.

Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1

Affiliations

Uncoupling histone modification crosstalk by engineering lysine demethylase LSD1

Kwangwoon Lee et al. Nat Chem Biol. 2025 Feb.

Abstract

Biochemical crosstalk between two or more histone modifications is often observed in epigenetic enzyme regulation, but its functional significance in cells has been difficult to discern. Previous enzymatic studies revealed that Lys14 acetylation of histone H3 can inhibit Lys4 demethylation by lysine-specific demethylase 1 (LSD1). In the present study, we engineered a mutant form of LSD1, Y391K, which renders the nucleosome demethylase activity of LSD1 insensitive to Lys14 acetylation. K562 cells with the Y391K LSD1 CRISPR knockin show decreased expression of a set of genes associated with cellular adhesion and myeloid leukocyte activation. Chromatin profiling revealed that the cis-regulatory regions of these silenced genes display a higher level of H3 Lys14 acetylation, and edited K562 cells show diminished H3 mono-methyl Lys4 near these silenced genes, consistent with a role for enhanced LSD1 demethylase activity. These findings illuminate the functional consequences of disconnecting histone modification crosstalk for a key epigenetic enzyme.

PubMed Disclaimer

Conflict of interest statement

Competing interests: P.A.C. is a co-founder of Acylin Therapeutics, which is involved in developing epigenetic agents, and has been a consultant for the pharmaceutical companies AbbVie and Constellation. He also is a co-inventor on US patent 11,565,994 B2 that concerns LSD1 and CoREST complex inhibitors. B.B.L. has received research funding from Eisai and AstraZeneca and is a shareholder and member of the scientific advisory board of Light Horse Therapeutics. The other authors declare no competing interests.

Similar articles

Cited by

References

    1. Kornberg RD Structure of chromatin. Annu Rev Biochem 46, 931–54 (1977). - PubMed
    1. Richmond TJ, Finch JT, Rushton B, Rhodes D & Klug A Structure of the nucleosome core particle at 7 Å resolution. Nature 311, 532–537 (1984). - PubMed
    1. Wang ZA & Cole PA The Chemical Biology of Reversible Lysine Post-translational Modifications. Cell Chemical Biology 27, 953–969 (2020). - PMC - PubMed
    1. Valencia-Sánchez MI et al. Structural Basis of Dot1L Stimulation by Histone H2B Lysine 120 Ubiquitination. Molecular Cell 74, 1010–1019.e6 (2019). - PMC - PubMed
    1. Worden EJ, Hoffmann NA, Hicks CW & Wolberger C Mechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L. Cell 176, 1490–1501.e12 (2019). - PMC - PubMed

LinkOut - more resources